News for Akebia Therapeutics Stock (AKBA)

ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

Newsfile Corp • 03/25/22

AKEBIA THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Akebia Therapeutics, I

PRNewsWire • 03/24/22

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

PRNewsWire • 03/23/22

AKBA LOSS ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

Newsfile Corp • 03/22/22

Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm

Business Wire • 03/22/22

ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA

Business Wire • 03/21/22

AKEBIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire • 03/18/22

AKBA EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

PRNewsWire • 03/16/22

SHAREHOLDER ALERT: Holzer & Holzer Announces a Class Action Was Filed on Behalf of Akebia Investors (AKBA) and Encourages Investors With Significant Losses to Contact the Firm

Newsfile Corp • 03/15/22

AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. (NASDAQ: AKBA)

PRNewsWire • 03/15/22

AKBA EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA

Business Wire • 03/15/22

7 Biotech Stocks With Key Catalysts in March

InvestorPlace • 03/09/22

Key FDA Decisions Soon on Akebia, Bristol-Myers and Novartis Drugs

GuruFocus • 03/07/22

3 Penny Stocks To Watch For Your List In March 2022

PennyStocks • 03/03/22

Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

PRNewsWire • 03/01/22

7 Speculative Penny Stocks Worth a Roll of the Dice

InvestorPlace • 02/25/22

Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch

PRNewsWire • 02/22/22

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business Highlights

PRNewsWire • 02/09/22

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (AKBA) Investigation

Business Wire • 01/27/22

Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference

PRNewsWire • 01/10/22

Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

PRNewsWire • 01/04/22

Akebia Therapeutics Announces Participation in Upcoming Investor Conferences

PRNewsWire • 11/24/21

Akebia Therapeutics to Present at Jefferies London Healthcare Conference

PRNewsWire • 11/15/21

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2021 Results - Earnings Call Transcript

Seeking Alpha • 11/09/21

Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones

PRNewsWire • 11/04/21